Deutetrabenazine for tardive dyskinesia: A systematic review of the efficacy and safety profile for this newly approved novel medication —What is the number needed to treat, number needed to harm and likelihood to be helped or harmed?

ConclusionsDeutetrabenazine is the second FDA‐approved agent specifically indicated for the treatment of TD. Head‐to‐head comparisons with other VMAT2 inhibitors among patients with TD in the “real world” are needed.

Source: International Journal of Clinical Practice - October 1, 2017 Category: Internal Medicine Authors: Leslie Citrome Tags: SYSTEMATIC REVIEW Source Type: research